NASDAQ:CANC Tema Oncology ETF (CANC) Price, Holdings, & News → Bill Clinton Backing Biden Replacement??? (From The Freeport Society) (Ad) Free CANC Stock Alerts $27.86 -0.10 (-0.36%) (As of 06/13/2024 ET) Add Compare Share Share Today's Range$27.68▼$27.9450-Day Range$25.27▼$27.9752-Week Range$21.26▼$29.16Volume5,134 shsAverage Volume4,210 shsMarket Capitalization$18.95 millionAssets Under Management$29.45 millionDividend Yield0.50%Net Expense Ratio0.75% Stock AnalysisStock AnalysisChartDividendHoldingsRatingsTrendsStock AnalysisChartDividendHoldingsRatingsTrends Get Tema Oncology ETF alerts: Email Address About Tema Oncology ETFThe Tema Oncology ETF (CANC) is an exchange-traded fund that mostly invests in health care equity. The fund is actively managed, investing in stocks of companies focused on cancer treatment and management from issuers all around the world. The fund uses a bottom-up approach to select pioneering companies at perceived attractive valuations CANC was launched on Aug 15, 2023 and is issued by Tema.Read More CANC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CANC ETF News HeadlinesNo headlines for this company have been tracked by MarketBeat.com Receive CANC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tema Oncology ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address Fund Details IssuerTema Global Fund NameTema Oncology ETF Tax ClassificationRegulated Investment Company Stock ExchangeNASDAQCurrent SymbolNASDAQ:CANC Inception Date8/15/2023 Fund ManagerDavid Song WebN/A PhoneN/AFund Focus Asset ClassEquity BenchmarkN/A CategoryStrategy FocusTheme Development LevelDeveloped Markets RegionGlobal Number of Holdings49 Fund Statistics Assets Under Management$29.45 million Average Daily Volume$0.00 Discount/Premium0.19% Administrator, Advisor and Custodian AdministratorUS Bancorp Fund Services, LLC AdvisorTema Global Limited CustodianU.S. Bank, N.A. DistributorForeside Fund Services, LLC Transfer AgentU.S. Bancorp Fund Services, LLC TrusteeN/A Lead Market MakerVirtu Financial Miscellaneous Outstanding Shares680,000Beta1.11 Creation Unit10,000 Creation Fee$500.00 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Ad GoldenCrest MetalsBiden’s Tax Plan Could Destroy Your Retirement Savings!Leading economists are issuing stark warnings: The anticipated capital gains tax increase under President Biden could drastically undermine your retirement plans by 2025.Learn More Today Tema Oncology ETF ExpensesTypeCANCTheme ETFsEquity ETFsNASDAQ ETFsAll ETFsManagement Fee0.99%0.57%0.54%0.48%0.51%Other Expenses0.00%0.71%0.54%0.34%0.58%Total Expense0.99%0.72%0.70%0.58%0.70%Fee Waiver-0.24%-0.74%-0.54%-0.22%-0.56%Net Expense0.75%0.60%0.60%0.54%0.58% Tema Oncology ETF (CANC) Holdings & ExposureTop 10 CANC HoldingsRegeneron Pharmaceuticals(NASDAQ:REGN)Holding Weight: 5.70%Merck & Co., Inc.(NYSE:MRK)Holding Weight: 5.34%AstraZeneca PLCHolding Weight: 4.87%Daiichi Sankyo Co LtdHolding Weight: 4.52%Amgen(NASDAQ:AMGN)Holding Weight: 3.28%Novartis AG Registered SharesHolding Weight: 3.16%Illumina(NASDAQ:ILMN)Holding Weight: 3.10%Incyte(NASDAQ:INCY)Holding Weight: 3.04%Revolution Medicines(NASDAQ:RVMD)Holding Weight: 2.93%Blueprint Medicines(NASDAQ:BPMC)Holding Weight: 2.85%CANC Sector ExposureCANC Industry ExposureFull Holdings Details Similar ETFsJPMorgan Sustainable Infrastructure ETFNASDAQ:BLLDCarbon Collective Climate Solutions U.S. Equity ETFNASDAQ:CCSOGlobal X Blockchain & Bitcoin Strategy ETFNASDAQ:BITSFirst Trust Dow Jones International Internet ETFNASDAQ:FDNIiShares Emerging Markets Infrastructure ETFNASDAQ:EMIF CANC ETF - Frequently Asked Questions How have CANC shares performed in 2024? Tema Oncology ETF's stock was trading at $26.40 at the beginning of 2024. Since then, CANC shares have increased by 5.5% and is now trading at $27.8608. View the best growth stocks for 2024 here. How often does Tema Oncology ETF pay dividends? What is the dividend yield for Tema Oncology ETF? Tema Oncology ETF declared a Variable dividend on Tuesday, December 12th. Investors of record on Thursday, December 14th will be paid a dividend of $0.1491 per share on Friday, December 15th. The ex-dividend date of this dividend is Wednesday, December 13th. Read our dividend analysis for CANC. What does CANC invest in? Tema Oncology ETF is a equity fund issued by Tema Global. CANC focuses on theme investments. The fund's investments total to approximately $29.45 million assets under management. What stocks does Tema Oncology ETF hold? CANC invests in 49 holdings. Some of the stocks in their portfolio include Regeneron Pharmaceuticals (REGN), Merck & Co., Inc. (MRK), Amgen (AMGN), Illumina (ILMN), Incyte (INCY), Revolution Medicines (RVMD), Blueprint Medicines (BPMC), Mereo BioPharma Group (MREO), argenx (ARGX) and Moderna (MRNA). What is the management fee for Tema Oncology ETF? Tema Oncology ETF's management fee is 0.99% and has no other recorded expenses. However, CANC has a fee waiver of -0.24% to reimburse the expenses. The net expense ratio for CANC is 0.75%. How do I buy shares of Tema Oncology ETF? Shares of CANC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CANC) was last updated on 6/13/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBiden’s Tax Plan Could Destroy Your Retirement Savings!Leading economists are issuing stark warnings: The anticipated capital gains tax increase under President B...GoldenCrest Metals | SponsoredLike Investing in Big Tech in the Early 2000s?More than a decade after the first Bitcoin was mined, people are finally realizing something very important......Manward Press | SponsoredEstee Lauder, MAC, and other beauty brands are raving about this emerging NYSE AI companyA Little-known NYSE Company is Empowering the Beauty Industry with Innovative AI and AR Tools.Financial Markets Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredA once-in-a-century investment opportunityIt's an under-the-radar stock reshaping a projected $109 billion industry - And, I believe, has far more poten...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tema Oncology ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Tema Oncology ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.